<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183024</url>
  </required_header>
  <id_info>
    <org_study_id>SAIRB-17-0036</org_study_id>
    <nct_id>NCT03183024</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody</brief_title>
  <official_title>Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan A. Bernstein, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bernstein Clinical Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to determine the efficacy of benralizumab when compared to placebo in patients with
      chronic hives that do not respond to antihistamine treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with chronic hives that do not respond to antihistamine treatment and have hives of
      unknown cause will be eligible. Subjects who meet the inclusion/exclusion criteria after the
      run-in phase will receive 3 doses of study medication. The study also involved blood draws
      and a punch biopsy of a hive
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change in urticarial activity score averaged over 7 days- no units</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>subject completed form</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in blood anti-FCER1 level (kU/l)</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>specific lab test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood anti-TPO level (IU/L)</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>specific blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Blood ECP level (ug/L)</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>specific blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in blood eotaxin level (pg/ml)</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>specific blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in RNA testing</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>gene expression profile using RNA-sequencing in skin biopsy samples (lesional vs non-lesional skin) (log 2 fold-change)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in skin biopsy inflammatory cell counts</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>inflammatory cell count in skin biopsy (number of cells/sq mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in cytokine quantification in skin biopsy (units/mL)</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>skin biopsy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>change in blood pressure</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>blood pressure- mm Hg</description>
  </other_outcome>
  <other_outcome>
    <measure>change in pulse rate</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>pulse rate- bpm</description>
  </other_outcome>
  <other_outcome>
    <measure>change in blood urea nitrogen</measure>
    <time_frame>through study completion, up to 7 months</time_frame>
    <description>blood urea nitrogen lab test - mg/dl</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Idiopathic Urticaria</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for benralizumab sc given during run-in phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>benralizumab</intervention_name>
    <description>open-label treatment</description>
    <arm_group_label>benralizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>sterile water to mimic benralizumab</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hives for over 6 weeks of unknown cause hives most days of the despite use of
             antihistamines

        Exclusion Criteria:

          -  hives due to known reasons history of cancer pregnant or nursing History of HIV or
             Hepatitis recent parasitic infection currently or have received treatment with a
             monoclonal antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Murphy, BS, CCRC</last_name>
    <phone>5133541746</phone>
    <email>kmurphy@bernsteincrc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Murphy, BS, CCRC</last_name>
      <phone>513-354-1746</phone>
      <email>kmurphy@bernsteincrc.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bernstein Clinical Research Center</investigator_affiliation>
    <investigator_full_name>Jonathan A. Bernstein, MD</investigator_full_name>
    <investigator_title>PI/ co-owner</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

